# A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

> **NCT06298552** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **argenx** · enrollment: 119 (actual)

## Conditions studied

- Generalized Myasthenia Gravis
- gMG
- Myasthenia Gravis, Generalized
- Myasthenia Gravis

## Interventions

- **BIOLOGICAL:** Efgartigimod IV
- **OTHER:** Placebo IV

## Key facts

- **NCT ID:** NCT06298552
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-16
- **Primary completion:** 2025-06-30
- **Final completion:** 2027-06
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2025-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06298552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06298552, "A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06298552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*